ACE and Decreased liver function: To compare the risk of liver dysfunction among ACE inhibitors in a real-world setting in Japan and to consider whether any additional safety measures are necessary for ACE inhibitors that do not carry a PI warning, the Pharmaceuticals and Medical Devices Agency (PMDA) conducted a pharmacoepidemiological study to evaluate risk of liver dysfunction with ACE inhibitors available in Japan by utilizing the MID-NET®.